title: Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.
abstract: The pharmacokinetics of cefepime in 31 young, healthy volunteers were assessed after the administration of single and multiple 250-, 500-, 1,000-, or 2,000-mg intravenous doses. Each subject received a single dose of cefepime via a 30-min intravenous infusion on day 1 of the study. Starting from day 2, subjects received multiple doses of cefepime every 8 h for 9 days, and on the morning of day 11, they received the last dose. Serial blood and urine samples were collected after administration of the first dose and on days 1, 6, and 11. Cefepime concentrations in plasma and urine were assayed by using reverse-phase high-performance liquid chromatography with UV detection. Data were evaluated by noncompartmental methods to determine pharmacokinetic parameters. The mean half-life of cefepime was approximately 2 h and did not vary with the dose or duration of dosing. The regression analyses of peak levels (Cmax) in plasma at the end of the 30-min intravenous infusion and the area under the plasma concentration-versus-time curve (AUCo-infinity) showed a dose-proportional response. The steady-state volume of distribution (Vss) was approximately 18 liters and was independent of the administered dose. The multiple-dose pharmacokinetic data are suggestive of a lack of accumulation or change in clearance of cefepime on repeated dosing. Cefepime was excreted primarily unchanged in urine. The recovery of intact cefepime in urine was invariant with respect to the dose and accounted for over 80% of the dose. The values for renal clearance ranged from 99 to 132 ml/min and were suggestive of glomerular filtration as the primary excretion mechanism. It is concluded that cefepime linear pharmacokinetics in healthy subjects.
authors.affiliation: Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Syracuse, New York 13221-4755, USA.
authors.forename: R H
authors.initials: RH
authors.lastname: Barbhaiya
authors.forename: S T
authors.initials: ST
authors.lastname: Forgue
authors.forename: C R
authors.initials: CR
authors.lastname: Gleason
authors.forename: C A
authors.initials: CA
authors.lastname: Knupp
authors.forename: K A
authors.initials: KA
authors.lastname: Pittman
authors.forename: D J
authors.initials: DJ
authors.lastname: Weidler
authors.forename: H
authors.initials: H
authors.lastname: Movahhed
authors.forename: J
authors.initials: J
authors.lastname: Tenney
authors.forename: R R
authors.initials: RR
authors.lastname: Martin
mesh_terms: D000328:Adult; D000077723:Cefepime; D002511:Cephalosporins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male
chemical_list: D002511:Cephalosporins; D000077723:Cefepime